source
- Kamau Therapeutics presents first clinical data from its updated sickle-cell gene-editing programKamau Therapeutics, a biotech company that entered the scene in 2023, has released clinical data from its reengineered sickle‑cell gene‑editing program for the first time. The disclosure marks the…
- Biotech startups opt out of AI for drug discovery, say STATThe latest STAT AI Prognosis newsletter notes that a number of biotech startups are deliberately avoiding artificial intelligence in their drug discovery programs. These companies argue that AI ma…